Diana Brixner, PhD, and Ashley Peterson, MHA, explore the distinctions between prescription digital therapeutics (PDTs) and wellness mobile apps, addressing the role of insurance coverage and the clinical validation requirements that payers consider when determining whether to cover PDTs as a treatment modality.
In VERIFY, Rusfertide Spares Most Patients With PV a Phlebotomy for 32 Weeks, Improves QOL
June 3rd 2025Adding rusfertide to standard of care more than doubled the share of patients with polycythemia vera (PV) who did not meet criteria for a phlebotomy, according to data from the VERIFY trial.
Read More